StreetInsider.com News Articles

Replimune Group (REPL) PT Raised to $21 at JPMorgan

Wed, 26 Aug 2026 08:49:01 -0400

JPMorgan analyst Anupam Rama raised the price target on Replimune Group (NASDAQ: REPL) to $21.00 (from $20.00) while maintaining a Overweight rating.

Form 4 Replimune Group, Inc. For: Aug 20 Filed by: Astley-Sparke Philip

Mon, 24 Aug 2026 19:49:00 -0400

si-local-file:///var/storage/secattach/20260824/26969511.html

Form 4 Replimune Group, Inc. For: Aug 20 Filed by: Astley-Sparke Philip

Mon, 24 Aug 2026 19:49:00 -0400

si-local-file:///var/storage/secattach/20260824/26969511.html

Form 4 Replimune Group, Inc. For: Aug 17 Filed by: Hill Emily Luisa

Wed, 19 Aug 2026 18:42:00 -0400

si-local-file:///var/storage/secattach/20260819/26951460.html

Form 4 Replimune Group, Inc. For: Aug 17 Filed by: Hill Emily Luisa

Wed, 19 Aug 2026 18:42:00 -0400

si-local-file:///var/storage/secattach/20260819/26951460.html

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 19 Aug 2026 16:01:00 -0400

WOBURN, Mass., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to Michelle DiNapoli, the Company’s Chief Commercial Officer.

The inducement awards consist of a non-qualified stock option to purchase 150,000 shares of the Company's common stock and restricted stock units representing 100,000 shares of the Company's common stock. The option has an exercise price of $15.58 per share, which is equal to the closing price of the Company's common stock on the date of

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 19 Aug 2026 16:01:00 -0400

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 19 Aug 2026 16:01:00 -0400

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 19 Aug 2026 16:01:00 -0400

Form S-3ASR Replimune Group, Inc.

Fri, 14 Aug 2026 16:53:00 -0400

si-local-file:///var/storage/secattach/20260814/26932259.html

Form S-3ASR Replimune Group, Inc.

Fri, 14 Aug 2026 16:53:00 -0400

si-local-file:///var/storage/secattach/20260814/26932259.html

Form 10-Q Replimune Group, Inc. For: Jun 30

Fri, 14 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260814/26930467.html

Form 10-Q Replimune Group, Inc. For: Jun 30

Fri, 14 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260814/26930467.html

Form SCHEDULE 13G/A Replimune Group, Inc. Filed by: Ridgeback Capital Investments L.P.

Fri, 14 Aug 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260814/26929884.html

Form SCHEDULE 13G/A Replimune Group, Inc. Filed by: Ridgeback Capital Investments L.P.

Fri, 14 Aug 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260814/26929884.html

Form 8-K Replimune Group, Inc. For: Aug 14

Fri, 14 Aug 2026 08:11:00 -0400

si-local-file:///var/storage/secattach/20260814/26924970.html

Form 8-K Replimune Group, Inc. For: Aug 14

Fri, 14 Aug 2026 08:11:00 -0400

si-local-file:///var/storage/secattach/20260814/26924970.html

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

Fri, 14 Aug 2026 08:00:00 -0400

TUDRIQEV™ in combination with nivolumab receives FDA accelerated approval and will launch within 60 days

Michelle DiNapoli appointed as Chief Commercial Officer

Recently completed financing extends cash runway to support commercial launch and confirmatory trial

WOBURN, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal first quarter ended June 30, 2026 and provided a business update.

On August 6, 2026, the Company announced the U.S. Food and Drug Administration (FDA)

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

Fri, 14 Aug 2026 08:00:00 -0400

TUDRIQEV™ in combination with nivolumab receives FDA accelerated approval and will launch within 60 days

Michelle DiNapoli appointed as Chief Commercial Officer

Recently completed financing extends cash runway to support commercial launch and confirmatory trial

On August 6, 2026, the Company announced the U.S. Food and Drug Administration (FDA)

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

Fri, 14 Aug 2026 08:00:00 -0400

TUDRIQEV™ in combination with nivolumab receives FDA accelerated approval and will launch within 60 days

Michelle DiNapoli appointed as Chief Commercial Officer

Recently completed financing extends cash runway to support commercial launch and confirmatory trial

On August 6, 2026, the Company announced the U.S. Food and Drug Administration (FDA)

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

Fri, 14 Aug 2026 08:00:00 -0400

TUDRIQEV™ in combination with nivolumab receives FDA accelerated approval and will launch within 60 days

Michelle DiNapoli appointed as Chief Commercial Officer

Recently completed financing extends cash runway to support commercial launch and confirmatory trial

On August 6, 2026, the Company announced the U.S. Food and Drug Administration (FDA)

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

Fri, 14 Aug 2026 08:00:00 -0400

TUDRIQEV™ in combination with nivolumab receives FDA accelerated approval and will launch within 60 days

Michelle DiNapoli appointed as Chief Commercial Officer

Recently completed financing extends cash runway to support commercial launch and confirmatory trial

On August 6, 2026, the Company announced the U.S. Food and Drug Administration (FDA)

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

Fri, 14 Aug 2026 08:00:00 -0400

TUDRIQEV™ in combination with nivolumab receives FDA accelerated approval and will launch within 60 days

Michelle DiNapoli appointed as Chief Commercial Officer

Recently completed financing extends cash runway to support commercial launch and confirmatory trial

On August 6, 2026, the Company announced the U.S. Food and Drug Administration (FDA)

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

Fri, 14 Aug 2026 08:00:00 -0400

TUDRIQEV™ in combination with nivolumab receives FDA accelerated approval and will launch within 60 days

Michelle DiNapoli appointed as Chief Commercial Officer

Recently completed financing extends cash runway to support commercial launch and confirmatory trial

On August 6, 2026, the Company announced the U.S. Food and Drug Administration (FDA)

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

Fri, 14 Aug 2026 08:00:00 -0400

TUDRIQEV™ in combination with nivolumab receives FDA accelerated approval and will launch within 60 days

Michelle DiNapoli appointed as Chief Commercial Officer

Recently completed financing extends cash runway to support commercial launch and confirmatory trial

On August 6, 2026, the Company announced the U.S. Food and Drug Administration (FDA)